Top 10 Companies in the (S)-1-[2-(Trifluoromethyl)Phenyl]Ethylamine Market (2026): Market Leaders Powering Global Synthesis

MARKET INSIGHTS

Global (S)-1-[2-(Trifluoromethyl)Phenyl]Ethylamine market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 54.7 million by 2034, exhibiting a CAGR of 6.9% during the forecast period.

(S)-1-[2-(Trifluoromethyl)Phenyl]Ethylamine is a chiral amine compound characterized by a trifluoromethyl group positioned at the ortho position of the phenyl ring, with a defined (S)-stereochemical configuration at the ethylamine center. This specialty fine chemical serves as a critical building block and chiral auxiliary in asymmetric synthesis, widely utilized in the development of active pharmaceutical ingredients (APIs), agrochemicals, and advanced intermediates where precise stereochemical control is essential to biological activity and efficacy.

The market is gaining steady momentum, driven by the expanding demand for enantiopure compounds in pharmaceutical synthesis and the broader industry shift toward stereoselective manufacturing processes. The trifluoromethyl moiety imparts enhanced metabolic stability, lipophilicity, and bioavailability to drug candidates, making this compound particularly valuable in medicinal chemistry pipelines. Leading fine chemical and custom synthesis companies such as Sigma‑Aldrich (Merck KGaA), TCI Chemicals, and Fluorochem Ltd. are actively supplying this compound to research institutions and pharmaceutical manufacturers globally, reinforcing its commercial relevance across the forecast period.

(S)-1-[2-(Trifluoromethyl)Phenyl]Ethylamine Market – View in Detailed Research Report

Top 10 Companies

---

10️⃣ 1. Sigma‑Aldrich (Merck KGaA)

Headquarters: Darmstadt, Germany
Key Offering: Pharmaceutical‑grade chiral intermediates and custom synthesis services

Sigma‑Aldrich’s extensive portfolio of chiral building blocks positions it as a trusted partner for pharmaceutical R&D. The company’s state‑of‑the‑art asymmetric hydrogenation platforms deliver consistently high enantiomeric excess, ensuring compliance with stringent regulatory standards.

Sustainability & Growth Initiatives:

• Investment in scalable, low‑energy asymmetric catalysis to reduce carbon footprint.
• Partnerships with university laboratories to accelerate discovery of fluorinated APIs.
• Implementation of a digital analytics platform for real‑time quality monitoring.

---

9️⃣ 2. TCI Chemicals

Headquarters: Tokyo, Japan
Key Offering: Custom synthesis of chiral amines and specialty intermediates

TCI’s expertise in chiral resolution and biocatalysis enables it to deliver high‑purity intermediates at scale. The firm’s focus on process optimization translates into cost advantages for its pharmaceutical clients.

Sustainability & Growth Initiatives:

• Adoption of enzymatic pathways to replace hazardous reagents.
• Development of a closed‑loop solvent recycling system.
• Collaboration with industry consortia to standardise chiral purity metrics.

---

8️⃣ 3. Fluorochem Ltd.

Headquarters: London, United Kingdom
Key Offering: Fluorinated chiral amines and advanced intermediates

Fluorochem’s proprietary synthesis routes for (S)-1-[2-(Trifluoromethyl)Phenyl]Ethylamine provide rapid access to high‑purity material, supporting accelerated drug development timelines.

Sustainability & Growth Initiatives:

• Integration of renewable feedstocks in fluorination steps.
• Optimization of waste‑water treatment to meet EU environmental directives.
• Engagement with regulatory bodies to streamline approval pathways for chiral intermediates.

---

7️⃣ 4. Capot Chemical Co., Ltd.

Headquarters: Shenzhen, China
Key Offering: High‑purity chiral intermediates and custom synthesis solutions

Capot’s advanced asymmetric hydrogenation reactors and robust quality systems have earned it a dominant position in the Asian market, supplying both domestic and international pharmaceutical clients.

Sustainability & Growth Initiatives:

• Expansion of plant capacity with energy‑efficient equipment.
• Implementation of a digital traceability platform for raw materials.
• Participation in joint R&D initiatives with leading universities.

---

6️⃣ 5. PharmaBlock Sciences Co., Ltd.

Headquarters: Guangzhou, China
Key Offering: Chiral auxiliaries and resolution agents for complex synthesis

PharmaBlock’s expertise in chiral resolution techniques supports the development of next‑generation CNS drugs, offering tailored solutions for pharmaceutical manufacturers.

Sustainability & Growth Initiatives:

• Adoption of green chemistry principles across the production line.
• Collaboration with industry partners to reduce solvent usage.
• Development of a real‑time purity monitoring system.

---

5️⃣ 6. Finetech Industry Limited

Headquarters: Shanghai, China
Key Offering: Custom chiral synthesis and scale‑up services

Finetech’s flexible production capabilities enable rapid response to market demand, making it a preferred supplier for small‑batch, high‑purity intermediates.

Sustainability & Growth Initiatives:

• Implementation of a waste‑minimisation program.
• Use of bio‑based catalysts in key steps.
• Engagement with local universities for talent development.

---

4️⃣ 7. Hairui Chemical Co., Ltd.

Headquarters: Shanghai, China
Key Offering: Advanced chiral intermediates and resolution agents

Hairui’s high‑throughput synthesis platforms support the rapid delivery of (S)-1-[2-(Trifluoromethyl)Phenyl]Ethylamine to pharmaceutical developers, ensuring consistent enantiomeric excess.

Sustainability & Growth Initiatives:

• Deployment of renewable energy sources across facilities.
• Development of a closed‑loop recycling system for solvents.
• Collaboration with industry consortia to standardise quality metrics.

---

3️⃣ 8. Shanghai Trustin Chemical Co., Ltd.

Headquarters: Shanghai, China
Key Offering: Chiral building blocks and custom synthesis

Shanghai Trustin’s robust supply chain and ISO‑certified processes make it a reliable partner for global pharmaceutical manufacturers seeking high‑purity intermediates.

Sustainability & Growth Initiatives:

• Investment in energy‑efficient reactors.
• Implementation of a digital quality management system.
• Partnerships with research institutions to explore novel fluorination methods.

---

2️⃣ 9. Ningbo Inno Pharmchem Co., Ltd.

Headquarters: Ningbo, China
Key Offering: Custom synthesis of chiral intermediates and small‑batch production

Ningbo Inno’s agile manufacturing model allows it to cater to niche markets, delivering high‑purity material on short lead times.

Sustainability & Growth Initiatives:

• Adoption of green chemistry practices in all synthesis steps.
• Implementation of a waste‑water treatment system compliant with local regulations.
• Engagement with local universities to develop talent in chiral chemistry.

---

1️⃣ 10. Enamine Ltd.

Headquarters: Kyiv, Ukraine
Key Offering: Custom synthesis and rapid scale‑up of chiral intermediates

Enamine’s flexible production capacity and expertise in chiral resolution make it a valuable partner for pharmaceutical developers seeking cost‑effective solutions.

Sustainability & Growth Initiatives:

• Investment in energy‑efficient processes.
• Development of a digital platform for real‑time purity monitoring.
• Collaboration with industry partners to promote sustainable synthesis routes.

---

Download FREE Sample Report: (S)-1-[2-(Trifluoromethyl)Phenyl]Ethylamine Market – View in Detailed Research Report

Get Full Report: (S)-1-[2-(Trifluoromethyl)Phenyl]Ethylamine Market – View in Detailed Research Report

OUTLOOK

Over the next decade, the (S)-1-[2-(Trifluoromethyl)Phenyl]Ethylamine market will be shaped by the continued rise of fluorine‑containing drug candidates, the need for high‑purity chiral intermediates in CNS and metabolic disease therapeutics, and the growing preference for green chemistry in fine chemical manufacturing. Companies that can deliver scalable, cost‑effective production while maintaining stringent enantiomeric purity will secure the largest share of this expanding market.

FUTURE TRENDS

• Biocatalytic synthesis: Engineered transaminases and reductive aminases are reducing reliance on expensive chiral metal catalysts, lowering production costs and environmental impact.
• Digitalisation of quality control: Real‑time analytics and AI‑driven process optimisation enable rapid detection of purity deviations, improving yield and consistency.
• Integrated supply chains: Partnerships between fine chemical suppliers and contract development and manufacturing organisations (CDMOs) streamline access to chiral intermediates for late‑stage synthesis.
• Regulatory convergence: Harmonised global standards for chiral purity are simplifying market entry for manufacturers across regions.